Skip to main content
. Author manuscript; available in PMC: 2020 Jul 1.
Published in final edited form as: Ocul Surf. 2019 Mar 22;17(3):551–559. doi: 10.1016/j.jtos.2019.03.006

Figure 5: Modes of action of ISG15 to inhibit ZIKV infection.

Figure 5:

(A) rISG15 was incubated with ZIKV (106 PFU/ml) for specified time points at 37°C followed by viral titer estimation by plaque assay. The values have been expressed as PFU/ml. (B) The Vero cells were treated with rISG15 for 1h prior to ZIKV infection at 4°C. The cells were infected at 4°C followed by RNA isolation and qPCR for ZIKV Envelope gene. The values have been expressed as RNA copies/μg. (C) The Vero cells were treated with rISG15 for 1h prior to ZIKV infection followed by challenge with ZIKV at 37°C. qPCR was performed for ZIKV envelope gene and the values have been expressed as RNA copies/μg of total RNA. (D) Schematic representation of the role of ISG15 in inhibiting ZIKV replication in mammalian cells. Data is presented as mean ± SD, * p<0.05, ** p<0.005, *** p<0.0005, One way-ANOVA.